The future of engineered immune cell therapies

The evolution of synthetic receptor systems

(2022) Janvie Manhas et al.   Nature Chemical Biology

HLA-independent T cell receptors for targeting tumors with low antigen density

(2022) Jorge Mansilla-Soto et al.   NATURE MEDICINE

CAR T cells produced in vivo to treat cardiac injury

(2022) Joel G. Rurik et al.   SCIENCE

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors

(2022) Louai Labanieh et al.   CELL

Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells

(2022) Pritha Agarwalla et al.   NATURE BIOTECHNOLOGY

Engineered cellular immunotherapies in cancer and beyond

(2022) Amanda V. Finck et al.   NATURE MEDICINE

Study Design: Human Leukocyte Antigen Class I Molecule A∗02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation

(2022) Katharina Schreeb et al.   Kidney International Reports

Potentiating adoptive cell therapy using synthetic IL-9 receptors

(2022) Anusha Kalbasi et al.   NATURE

The Past, Present, and Future of Non-Viral CAR T Cells

(2022) Alex Moretti et al.   Frontiers in Immunology

Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains

(2022) Khloe S. Gordon et al.   Nature Biomedical Engineering

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

(2022) Jiqin Zhang et al.   NATURE

High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails

(2022) Brian R. Shy et al.   NATURE BIOTECHNOLOGY

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

(2021) Max Jan et al.   Science Translational Medicine

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

(2021) Nisha B. Nagarsheth et al.   NATURE MEDICINE

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Situ Programming of CAR T Cells

(2021) Neha N. Parayath et al.   Annual Review of Biomedical Engineering

Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis

(2021) Sabina Kaczanowska et al.   CELL

SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models

(2021) Axel Hyrenius-Wittsten et al.   Science Translational Medicine

Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors

(2021) Yue Liu et al.   Science Translational Medicine

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

(2021) Jay Y. Spiegel et al.   NATURE MEDICINE

The promise of the gut microbiome as part of individualized treatment strategies

(2021) Daniel A. Schupack et al.   Nature Reviews Gastroenterology & Hepatology

CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus

(2021) Dimitrios Mougiakakos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Control of the activity of CAR-T cells within tumours via focused ultrasound

(2021) Yiqian Wu et al.   Nature Biomedical Engineering

Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control

(2021) Ian C. Miller et al.   Nature Biomedical Engineering

Engineering CAR-T cells to activate small-molecule drugs in situ

(2021) Thomas J. Gardner et al.   Nature Chemical Biology

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

(2021) Shaun Cordoba et al.   NATURE MEDICINE

CRISPR Screens to Identify Regulators of Tumor Immunity

(2021) Martin W. LaFleur et al.   Annual Review of Cancer Biology-Series

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

(2020) Katharina Reinhard et al.   SCIENCE

The Emerging Landscape of Immune Cell Therapies

(2020) Evan W. Weber et al.   CELL

Human chimeric antigen receptor macrophages for cancer immunotherapy

(2020) Michael Klichinsky et al.   NATURE BIOTECHNOLOGY

Metabolic labeling and targeted modulation of dendritic cells

(2020) Hua Wang et al.   NATURE MATERIALS

T cell-engaging therapies — BiTEs and beyond

(2020) Maria-Elisabeth Goebeler et al.   Nature Reviews Clinical Oncology

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

(2020) Nirav N. Shah et al.   NATURE MEDICINE

Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies

(2020) Ruth Dannenfelser et al.   Cell Systems

Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus

(2019) Rita Kansal et al.   Science Translational Medicine

Materials for Immunotherapy

(2019) C. Wyatt Shields et al.   ADVANCED MATERIALS

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

(2019) Patrick A. Baeuerle et al.   Nature Communications

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

(2019) Matthew B. Dong et al.   CELL

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours

(2019) Michael E. Coon et al.   Nature Biomedical Engineering

A guide to manufacturing CAR T cell therapies

(2018) Philipp Vormittag et al.   CURRENT OPINION IN BIOTECHNOLOGY

Rewiring T-cell responses to soluble factors with chimeric antigen receptors

(2018) ZeNan L Chang et al.   Nature Chemical Biology

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Balancing Safety and Innovation for Cell-Based Regenerative Medicine

(2018) Peter Marks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

(2018) Joseph A. Fraietta et al.   NATURE

Biomaterial-assisted targeted modulation of immune cells in cancer treatment

(2018) Hua Wang et al.   NATURE MATERIALS

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

(2017) Yong-Chen Lu et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

(2016) M. V. Maus et al.   CLINICAL CANCER RESEARCH

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells

(2016) Lenka V. Hurton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

(2016) C. T. Ellebrecht et al.   SCIENCE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Rapid “Open-Source” Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification

(2008) Morgan L. Maeder et al.   MOLECULAR CELL